KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 125 filers reported holding KEROS THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,787,221 | -17.1% | 212,899 | +4.5% | 0.00% | -50.0% |
| Q2 2023 | $8,183,983 | +8.1% | 203,683 | +14.9% | 0.00% | 0.0% |
| Q1 2023 | $7,569,429 | -9.8% | 177,270 | +1.4% | 0.00% | 0.0% |
| Q4 2022 | $8,392,168 | +36.9% | 174,764 | +7.3% | 0.00% | +100.0% |
| Q3 2022 | $6,130,000 | +47.4% | 162,947 | +8.3% | 0.00% | 0.0% |
| Q2 2022 | $4,158,000 | -48.5% | 150,501 | +1.3% | 0.00% | 0.0% |
| Q1 2022 | $8,076,000 | -10.5% | 148,517 | -3.7% | 0.00% | 0.0% |
| Q4 2021 | $9,020,000 | +52.4% | 154,172 | +3.0% | 0.00% | 0.0% |
| Q3 2021 | $5,918,000 | -10.1% | 149,620 | -3.4% | 0.00% | 0.0% |
| Q2 2021 | $6,580,000 | -16.4% | 154,938 | +21.2% | 0.00% | 0.0% |
| Q1 2021 | $7,871,000 | -17.5% | 127,870 | -5.5% | 0.00% | -50.0% |
| Q4 2020 | $9,540,000 | +196.7% | 135,241 | +62.3% | 0.00% | +100.0% |
| Q3 2020 | $3,215,000 | -2.2% | 83,346 | -4.9% | 0.00% | 0.0% |
| Q2 2020 | $3,288,000 | – | 87,655 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CHI Advisors LLC | 407,633 | $12,995,340 | 5.15% |
| Opaleye Management Inc. | 360,400 | $11,489,552 | 3.74% |
| Parkman Healthcare Partners LLC | 298,475 | $9,515,383 | 1.74% |
| BRAIDWELL LP | 1,357,309 | $43,271,011 | 1.37% |
| First Light Asset Management, LLC | 421,438 | $13,435,443 | 1.28% |
| Orbimed Advisors | 1,514,734 | $48,289,720 | 1.03% |
| Yiheng Capital Management, L.P. | 554,151 | $17,666,334 | 0.90% |
| Nantahala Capital Management | 328,781 | $10,481,538 | 0.90% |
| DAFNA Capital Management LLC | 65,961 | $2,102,837 | 0.65% |
| EDBI Pte Ltd | 10,105 | $322,147 | 0.35% |